<DOC>
	<DOC>NCT01333436</DOC>
	<brief_summary>This study will evaluate whether fasting/postprandial serum ApoB-48 levels are increased in diabetic participants compared to nondiabetic participants with the same range of serum LDL-C levels, and whether ApoB-48 levels can be used, along with LDL-C levels, to identify potential cardiovascular disease risk.</brief_summary>
	<brief_title>A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Inclusion criteria: Participant has an LDLC ranging from ≥100 mg/dL to &lt;160 mg/dL. Patient has a triglyceride (TG) level of ≤500 mg/dL. Participant treated with a lipidlowering agent in the 6 weeks prior to Visit 1 (screening period). Participant has active liver disease or persistent unexplained serum transaminase elevations (≥2 x the upper limit of normal [ULN]) Participant has increased creatine kinase (CK) (≥2 x ULN). Participant has a history of type 1 diabetes mellitus, ketoacidosis, or gestational diabetes mellitus. Participant has a history of alcohol and/or drug abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>